

IL-23-INDUCED PSORIASIS MODEL

Psoriasis is a chronic immune-mediated inflammatory skin disease, multifaceted in pathogenesis:

- · Involves interplay between genetic predisposition, immune system dysregulation, and environmental triggers
- Characterized histologically by epidermal thickening resulting from hyperproliferation of keratinocytes, immune cell infiltration into the skin, and parakeratosis
- Pathology associated with cytokine dysregulation and the JAK and STAT signaling pathways, with the primary driver being the IL-23/IL-17 pathway
- Therapeutic treatments exist; however, significant challenges persist: treatment adverse effects and resistance to conventional therapies

The IL-23-induced psoriasis model is translational into the clinic, bearing significant hallmarks of the human disease.


PRECLINICAL IN VIVO MODELS


Model	Development of Phenotype	Pros	Cons	Scientific Readouts
Recombinant IL- 23-induced Model	Daily intradermal injection of rIL-23	 Activation of the IL-23/IL-17 pathway produces many of the hallmarks of psoriasis Single cytokine used Published transcriptomic data suggest that this model more closely resembles human disease Validated model that is fast and reproducible 	 Significant differences between human and mouse skin – mouse models do not mimic all aspects of disease Limited inflammation observed due to activation of a single pathway Cost of rIL-23 	 In Vivo Daily bodyweight and ear caliper measurements Digital images* Ear skin macroscopic observations Ex Vivo H&E staining of ear sections* Epidermal and dermal thickness* Ear weight Histopathological assessment (parakeratosis, neutrophilic abscess, cellularity)* Cytokine analysis* mRNA level of cytokines*
IMQ (Aldara)- induced Model	Application of Aldara/IMQ (TLR 7/8 agonist) leads to IL-23 production by dendritic cells thereby driving IL-17A-dependent skin inflammation	 More enhanced inflammation observed Topical application Relatively inexpensive Validated model that is fast and reproducible 	 Complexity in mechanism of action of Aldara Vehicle used augments inflammation in a non-TLR dependent manner 	

*available on request. Extra cost may apply to additional services.

IL-23-INDUCED PSORIASIS MODEL VALIDATION DATA


- Mouse
 - SPF female C57BL/6J aged 6-8 weeks
 - Model - Psoriasis induced by daily intradermal injections of rIL-23 into the mouse ear for 4 consecutive days
- Test article administration
- Oral, intraperitoneal, intravenous, subcutaneous, or topical (other routes available on request)
- Statistically significant increase in ear thickness, ear weight, and IL-17A in the ear pinna of mice on days 2, 3, and 4







IL-23-INDUCED PSORIASIS MODEL VALIDATION DATA

- Anti-IL-23 was administered via i.p. or s.c. route 4 hours prior to IL-23 injection on day 0 and 2
- Blocking of IL-23 resulted in a statistically significant decrease in ear thickness and ear weight, with a corresponding decrease in the • levels of IL-17A, IL-17F, and IL-22 in the ear pinna of mice on day 4 (measured by both ELISA and mRNA expression analysis)







4

SUMMARY

The utilization of in vivo models represents a critical approach in studying the underlying mechanisms of disease. The IL-23 induced model leads to histopathological changes that are characteristic of human disease, thereby offering a highly relevant and clinically translatable framework for assessing therapeutic efficacy of anti-psoriasis therapies.

The IL-23 induced psoriasis model is a cost-effective, fast, validated model with prior tested data from anti-inflammatory compounds.

LEARN MORE AT CHEMPARTNER.COM/SERVICES/BIOLOGY-PHARMACOLOGY/IMMUNOLOGY-AND-INFLAMMATION